Drug Pipeline
When the FDA approves a “supplemental indication” for a drug already on the market — permitting it to be used for new conditions or stages of a disease, or additional patient... More
Briefing
“High-Cost Drugs”
31 result(s)
Cost Management
High Drug Prices: Who is Responsible?
With prescription drug prices very much in the news, the question often asked is: Who is responsible for high drug prices? Pharmaceutical manufacturers — and no one else — set... More
Commentary
Cost Management
Our formulary strategies effectively leverage competition in the pharmaceutical market to help reduce costs and trend for PBM clients. More
Video
Drug Pipeline
Scientific developments are altering the pace and focus of specialty drug development, while regulatory changes are shortening approval times. This poses new challenges for payors... More
Briefing
Specialty
While the launch time is uncertain, potential PAH generics could give payors greater cost control opportunities for a complex, expensive condition requiring lifelong treatment. More
Briefing
Cost Management
Real-time, member-specific benefit information across all points of care, helps provide greater price transparency, improves access to lower-cost alternatives, and makes... More
Briefing
Cost Management
We want clients and members to get the most out of their benefit and the cost of a drug is aligned with the value it delivers. Despite AWP inflation near 10%, we kept drug price... More
Feature
Pharmacy Innovation
Point-of-sale rebates and zero-dollar copay plans can help alleviate the impact of high drug costs for members in HDHPs during the deductible phase. More
Commentary
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature
Cost Management
CVS Health is launching real-time benefits which, for the first time ever, will offer members and their health care providers transparent, real-time access to member-specific... More
Briefing